menu toggle
As we continue to evolve our brand to Cencora, you will continue to see visual changes. We will be sunsetting amerisourcebergen.com over time and are actively moving content and information over to cencora.com. Please visit cencora.com if you can't find what you are looking for here.

Are US payers getting to grips with cost-effectiveness analysis?

By AmerisourceBergen

Cost-effectiveness analysis (CEA) is widely used in many countries as part of the broader approach to the health technology assessment (HTA) decision process. It’s common in countries with a national or asocial health insurance system where there is a single payer making decisions for the larger population.

In the US, with the multi-payer system, the process is more complex and interpretation expertise of CEAs may vary, making CEA utilization among payers limited.

Xcenda’s FormularyDecision team conducted a study to assess the current use of CEAs by US decision-makers, the challenges that they currently face in using CEAs, and the ways in which these could resolved. Download our research below.

Enter your information to download the report.